This stock is a great choice for cautious and aggressive investors.

What Happened? Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped 4% in the morning session after the company ...

The Coalition for Epidemic Preparedness Innovations said it will invest $54.3 million with Moderna to fund a Phase 3 trial of ...

As support from the U.S. government has evaporated, Moderna is leaning on an old ally to carry plans for its prospective mRNA ...

Moderna, Inc. has rallied ~23%, but rated a Sell due to deteriorating fundamentals. Learn more about MRNA stock here.

Since that moment, Moderna has taken steps to pave the path to long-term growth -- from cutting costs to focusing on its vast ...

Get the latest Moderna (MRNA) stock analysis: balanced risk-reward, new vaccine launches, and pipeline insights. See why we ...

Moderna will get up to $54.3 million in funding from a global coalition to support late-stage development of its experimental ...

After donating $176 million in proceeds from his original stock options in 2023, Stéphane Bancel is taking a different path ...

NEXSPIKE is Moderna’s third product to receive a positive CHMP opinion alongside Spikevax (COVID-19 Vaccine, mRNA) and mRESVIA (Respiratory Syncytial Virus Vaccine) mNEXSPIKE will be available in the ...

Both vaccines work. But Pfizer requires a longer waiting period before the vaccine kicks in, while Moderna has stronger side effects.

Stéphane Bancel, Moderna’s founding chief executive, has sold his six-level Beacon Hill townhouse after owning in the ...